Thrivelab is a clinical menopause service whose public FAQ makes a useful distinction: it describes compounded hormone prescriptions and acknowledges that compounded bioidentical hormone therapy is not FDA approved. For someone comparing micronized progesterone offers, that statement deserves more attention than a broad promise about hormone balance. It tells you something about the advertised prescribing pathway, while leaving the finished medicine unidentified.
We reviewed Thrivelab’s menopause service, FAQ and medicine information on September 29, 2026. This review examines those published descriptions, including their limits. It does not establish that a particular person can receive care, that a named pharmacy will fill a prescription, or that one of the listed capsules is an approved generic. Those questions need answers tied to the actual proposed prescription.
Read this article by section
The clinical offer comes before the capsule name
Thrivelab’s menopause page advertises a consultation and clinician assessment, rather than an ordinary retail purchase of progesterone. The clinician may consider estrogen, progesterone or neither. A visitor therefore encounters two decisions: whether the service can assess their circumstances, and what treatment the clinician might subsequently propose. Neither decision can be made from the medicine table alone. The FAQ also describes state coverage that is still expanding. Its broader shipping language does not establish clinical access everywhere. Our Defy Medical review provides another example of a consultation-led offer whose treatment menu cannot settle the eventual preparation.
A 503A pharmacy description is not an approval statement
In its FAQ, Thrivelab says prescriptions are issued by licensed medical providers and prepared at a 503A compounding pharmacy. This is the provider’s description of its arrangements; we have not independently authenticated every dispensing pharmacy. More importantly, that description does not contradict its acknowledgment that the compounded therapy is unapproved. FDA explains that it does not review compounded drugs for safety, effectiveness and quality before marketing as it does approved medicines. The bioidentical and approval guide separates the hormone’s identity from the regulatory status of the preparation containing it. Neither a professional license nor a pharmacy designation supplies a missing product approval.
Read the table’s dates and unexplained abbreviations together
The medicine-price page contains progesterone capsule entries and table dates from April 2024 and February 2025. It uses labels including SB, SR and E4M. We do not expand those abbreviations into a verified release mechanism, ingredient list or current price agreement. Finding an older table on a current website does not establish that every row remains available today. A useful written clarification would identify the exact item behind the row, the pharmacy, the charge unit and whether the listed amount still applies. The micronized terminology guide explains why a processing word also needs a preparation-specific context.
Chemical identity cannot finish the ingredient check
Thrivelab’s FAQ describes bioidentical hormones in terms of their molecular relationship to hormones produced by the body. That does not disclose everything else inside a capsule. For comparison, the exact FDA Prometrium label describes plant starting material, chemical identity and a finished oral formulation containing peanut oil. That ingredient belongs to the labeled product; it cannot be assigned to an unidentified Thrivelab compound. Equally, the word bioidentical does not prove an absence of allergens. The prescription and the dispensing record need to identify the actual formulation before a pharmacist can address a product-specific ingredient concern.
Keep the service payment separate from the medicine row
The FAQ’s payment explanation separates consultation arrangements, medicines and laboratory costs. Its self-pay option is advertised at $49 per month paid quarterly, or $40 per month paid annually, plus $45 for each telehealth visit; it lists the initial self-pay appointment at $94. These commitments do not include a blanket medicine or laboratory allowance. It says benefit verification is needed and acknowledges that coverage can vary. This is not a promise that a listed insurer will cover a particular compounded prescription. The refund language is also limited: its satisfaction process considers clinical-care or appointment fees case by case, while excluding prescription refunds and partial Thrively payments. The same page publishes short-notice appointment charges. Ask for the selected plan’s entire written payment and cancellation schedule, rather than treating a medicine-table figure as the total cost of joining. An insurance submission and a confirmed benefit are different records. The FAQ specifies a charge of $84 for an initial appointment, or $15 for an existing patient’s appointment, when a no-show, cancellation or rescheduling falls within forty-eight hours. Those fees concern reserved clinical time, not the medicine itself. A change to the treatment proposal therefore should not be assumed to cancel the financial terms of the appointment. Obtain the current agreement before booking, particularly where the website’s older medicine table is being used to estimate costs.
A transatlantic comparison needs a different product record
Our Newson Clinic review concerns UK consultations and UK medicine information. It is useful for recognizing that a familiar hormone name may appear under different regulatory and access arrangements. It does not provide an alternative US dispensing route or demonstrate that Thrivelab supplies the UK preparation. Thrivelab’s own clinical-service description remains the relevant starting point for its offer. The route guide also keeps swallowing a capsule separate from vaginal or skin application. No comparison here supports changing the route of a prescribed medicine or importing instructions from a differently labeled product.
The missing document is the proposed preparation
A specific question for Thrivelab is: if progesterone is recommended, which finished preparation would be prescribed, which pharmacy would dispense it, and which ingredient and patient-information records would accompany it? That request follows the boundary between the published compounded pathway and an individual prescription. The clinician must still explain the treatment purpose and alternatives; the pharmacy can clarify the supplied formulation and its instructions. A promotional description of personalization cannot answer either question by itself. This review establishes an actual menopause-care offer with an explicitly compounded component, while leaving the exact micronized preparation, personal suitability and selected purchase terms unverified.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Thrivelab: Menopause hormone careProvider clinical-service description; treatment and access wording is not an individual prescribing or state-eligibility confirmation · Checked 2026-09-29
- Thrivelab: Frequently asked questionsProvider FAQ; separate membership, medication, state-access, laboratory and refund descriptions retain their stated limits · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- Thrivelab: Medication pricesProvider medication tables dated April 5, 2024 and February 19, 2025; current page access does not update historical prices or explain formulation codes · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29